|
Control (mean ±SD) |
Intervention (mean ±SD) |
p-value |
Age (years) |
60 ± 10.34 |
68.8 ± 5.97 |
0.14 |
Duration of Diabetes (years) |
13.6 ± 6.8 |
18 ± 5.48 |
0.29 |
|
Control, n(%) |
Intervention, n(%) |
|
Men |
5 (100%) |
4 (80%) |
0.37 |
History of CAD |
3 (60%) |
3 (60%) |
1 |
History of CKD |
4(80%) |
4(80%) |
1 |
| Stage 2: 2 (40%) |
Stage 2: 1 (20%) |
0.54 |
| Stage 3: 1 (20%) |
Stage 3: 3 (60%) |
0.58 |
| Stage 4: 0 (0%) |
Stage 4: 0 (0%) |
1 |
| Stage 5: 1 (20%) |
Stage 5: 0 (0%) |
0.35 |
Diabetic Medications: |
Oral HypoglycemicAgents |
2 (40%) |
1 (20%) |
0.54 |
Metformin |
2 (40%) |
2 (40%) |
1 |
Basal Insulin |
5 (100%) |
5 (100%) |
1 |
Prandial Insulin |
3 (60%) |
4 (80%) |
0.54 |
Other |
1 (20%) |
0 (0%) |
0.34 |
Medications: |
Statin Use |
4 (80%) |
4 (80%) |
1 |
ACE-I/ARB |
5 (100%) |
5 (100%) |
1 |
Beta-blocker |
4 (80%) |
4 (80%) |
1 |
|
